These agonists can improve insulin signaling, regulate glucose and lipid metabolism, and offer protection against Type 2 diabetes mellitus (T2DM) by stimulating AMPK activity in adipose tissue, liver, and muscle, irrespective of PPARγ activation [72,73,74]. This evidence concerns the gene PPARG and diabetes mellitus.